Naperville, IL -- (SBWire) -- 07/23/2013 --Reportstack, provider of premium market research reports announces the addition of Humira (Psoriasis) - Forecast and Market Analysis to 2022 market report to its offering
Humira (Psoriasis) - Forecast and Market Analysis to 2022

Summary

The publisher has released its new PharmaPoint Drug Evaluation report, Humira (Psoriasis) - Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

AbbVies Humira is a recombinant human IgG1 Monoclonal Antibody (mAb) that binds to TNF-? and blocks its interaction with p55 and p75 cell surface receptors, which reduces inflammation and stops tissue destruction. Humira reduces the epidermal thickness and the infiltration of inflammatory cells, such as TNF. It is the only fully-humanized mAb TNF inhibitor to enter the market for the treatment of PsO.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Humira including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Humira for the top 7 countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Humira performance
- Obtain sales forecast for Humira from 2012 to 2022 in the US, France, Germany, Italy, Spain, the UK and Japan.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/127706/humira-psoriasis-forecast-and-market-analysis-to-2022.html

Contact:
Ana Viste
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###